Cancer Patient Ceased Treatment After One Week
Due to Rapid Success
In the reported case, the patient, a
59-year-old female undergoing treatment at George Washington University for metastatic breast
cancer, experienced significant improvement in symptoms just one
week after initiating HT-001 therapy. Due to the swift resolution
of lesions and the alleviation of discomfort, the patient was able
to discontinue the treatment after just seven days. Over the
following three weeks, no new lesions developed, further
highlighting the potential of HT-001 as an effective and safe
therapy for EGFRI-associated PPEs.
NEW
YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company
focused on developing next-generation therapies for unmet medical
needs, is excited to announce positive data from the treatment of
epidermal growth factor receptor inhibitor (EGFRI) associated
papulopustular eruptions (PPEs) with its novel therapeutic
HT-001. During this first-of-its-kind human patient case, the
patient was able to cease treatment after just one week due to the
rapid and successful resolution of symptoms, marking a significant
advancement in managing a common and debilitating side effect
experienced by cancer patients undergoing EGFRI therapy.
EGFRIs are widely used to treat various cancers of epithelial
origin but are frequently associated with cutaneous side effects,
most notably PPEs like acneiform rash, which can occur in up to 90%
of patients. These PPEs can cause significant discomfort, including
pruritus and burning, and often lead to interruptions or
discontinuation of critical cancer therapies. HT-001 offers a new
approach to managing these skin toxicities, showing rapid symptom
relief without compromising the patient's ongoing cancer
treatment.
In the reported case, the patient, a 59-year-old female
undergoing treatment at George Washington
University for metastatic breast cancer, experienced
significant improvement in symptoms just one week after initiating
HT-001 therapy. Due to the swift resolution of lesions and the
alleviation of discomfort, the patient was able to discontinue the
treatment after just seven days. Over the following three weeks, no
new lesions developed, further highlighting the potential of HT-001
as an effective and safe therapy for EGFRI-associated PPEs.
"We are thrilled with the positive data from this first
investigator led study patient case," said Robb Knie, CEO of Hoth Therapeutics. "HT-001 has
the potential to significantly improve the quality of life for
cancer patients suffering from EGFRI-induced skin toxicities. This
rapid and successful treatment is an important milestone as we
continue to explore HT-001's potential to meet this critical unmet
need."
A Phase 2a clinical trial is currently underway to further
evaluate the efficacy and safety of HT-001 in the management of
EGFRI-associated skin toxicities. Current sites include MD Anderson
Cancer Center, University of Miami,
Dana Farber Cancer Institute, University of
California Irvine, the George
Washington University, Montefiore Medical Center, and
Northwell Health, Inc. For more information, please visit clinical
trials.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit
https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-data-from-first-of-its-kind-human-patient-treatment-of-egfri-associated-skin-toxicities-with-ht-001-302239044.html
SOURCE Hoth Therapeutics, Inc.